CD34 and plasma cell myeloma: A phase 3 clinical trial [10] in 2001 aimed on purging of autologous peripheral-blood stem cells using CD34 selection demonstrated that CD34 selection could significantly reduce myeloma cell contamination in SCC, but it did not reduce the risk of disease progression.